FERRAMOSCA, STEFANIA
FERRAMOSCA, STEFANIA
DIPARTIMENTO DI SCIENZE CLINICHE "LUIGI SACCO" (attivo dal 01/01/2002 al 27/04/2012)
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens
2011 D. Gonzalez de Requena, S. Bonora, O. Viganò, A. Calcagno, C. Cometto, A. D'Avolio, L. Baietto, V. Ghisetti, S. Magnani, S. Ferramosca, P. Vitiello, M. Galli, S. Rusconi, G. Di Perri
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART
2010 S. Rusconi, P. Vitiello, F. Adorni, S. Ferramosca, E. Focà, A. Capetti, P. Meraviglia, T. Quirino, S. Bonora, M. D’Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, V. Vullo, D. Francisci, M. Andreoni, E. Merlini, G. Marchetti
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses
2009 S. Rusconi, M. Lo Cicero, O. Viganò, F. Sirianni, E. Bulgheroni, S. Ferramosca, A. Bencini, A. Bianchi, L. Ruiz, C. Cabrera, J. Martinez-Picado, C.T. Supuran, M. Galli
In vitro efficacy of a non-conventional (folding) HIV-1 protease inhibitor without selection of resistance
2009 S. Ferramosca, M. Lo Cicero, A.E. Laface, F. Sirianni, E. Cesana, D. Provasi, G. Tiana, M. Galli, M. Moroni, A. Clivio, R.A. Broglia, S. Rusconi
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi
The non-conventional (folding) protease inhibitor blocks the human immunodeficiency virus type-1 replication without evidence of resistance during in vitro passage
2008 S. Ferramosca, M. Lo Cicero, A.E. Laface, F. Sirianni, E. Cesana, D. Provasi, G. Tiana, M. Galli, M. Moroni, A. Clivio, R.A. Broglia, S. Rusconi
Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy
2008 G. Marchetti, G.M. Bellistrì, E. Borghi, C. Tincati, S. Ferramosca, M. La Francesca, G. Morace, A. Gori, A. D'Arminio Monforte
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro
2007 S. Rusconi, M. Lo Cicero, S. Ferramosca, S. Sirianni, M. Galli, M. Moroni, A.E. Laface, E. Cesana, A. Clivio, G. Tiana, D. Provasi, R.A. Broglia